Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus.


Developing a new drug is expensive: the cost of going from bench to bedside is about $US1 billion. Therefore, the repurposing of an approved drug is potentially rewarding because it expands the drug's existing therapeutic profile and preempts additional development costs. As the safety profile of a repurposed drug is already well known, any new… (More)
DOI: 10.1111/wrr.12135

3 Figures and Tables


  • Presentations referencing similar topics